Merck's HCV Strategy Might Be: Get To Market, Then Improve Incrementally
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for intravenous drug users with hepatitis C might be an important niche indication while Merck gets triple combination NDA ready.
You may also be interested in...
No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.